The UPCI Flow Cytometry Facility moved to its new location at the Hillman Cancer Center Research Pavilion in September 2002. The new laboratory consists of a 200 ft 2 user laboratory (UserLab), and a 1000 ft 2 cell sorting laboratory. The Flow Cytometry Facility of the University of Pittsburgh Cancer Institute provides services to over 50 users within the UPCI and 20 non-UPCI users. These services fall into five categories: 1) Training users to operate the Facility's two user-dedicated analytical flow cytometers; 2) Performing high speed fluorescence activated cell sorting for investigators; 3) Insuring that the instruments in the facility are properly calibrated on a daily basis and advising users concerning the proper settings for their experiments; 4) Advising investigators on experimental design and data analysis and assisting in performance of complex multi-parameter experiments; and 5) Archiving all data produced by the facility. The current instrumentation at the UPCI Flow Cytometry Facility includes a Dako-Cytomation MoFLo high speed cell sorter, equipped with a CytoShield Biocontainment hood, a Dako-Cytomation CyAn 9-color high speed 9 color analyzer, and two Beckman Coulter XL 4-color analyzers. Despite the relocation to the Hillman Cancer Center, the usage of the flow cytometry facility has remained high, with cell sorting exclusive of setup time regularly exceeding 50% of absolute capacity (100 hours/month) and analytical cytometry exceeding 50% of business-hour capacity (160 hours/instrument/month). We anticipate that despite the loss of non-UPCI users resulting from the move, the recruitment of several new UPCI investigators and our continuing emphasis on education and training will more than make up for the loss of non-UPCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-19
Application #
7279240
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
19
Fiscal Year
2006
Total Cost
$113,120
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications